

1 10A NCAC 13D .2306 is readopted as published in 40:12 NCR 986-998 as follows:

2  
3 **10A NCAC 13D .2306 MEDICATION ADMINISTRATION**

4 (a) The facility shall ensure that medications are administered in accordance with applicable occupational licensure  
5 regulations and manufacturer's recommendations.

6 (b) The facility shall ensure that each patient's drug regimen is free from drugs used in excessive dose or duplicative  
7 therapy, for excessive duration or without indications for the prescription of the drug. Drugs shall not be used without  
8 monitoring or in the presence of adverse conditions that indicate the drugs' usage should be modified or discontinued.

9 As used in this Paragraph:

10 (1) "Excessive dose" means the total amount of any medication (including duplicate therapy) given at  
11 one time or over a period of time that is greater than the amount recommended by the manufacturer  
12 for a resident's age and condition.

13 (2) "Excessive Duration" means the medication is administered beyond the manufacturer's  
14 recommended time frames or facility-established stop order policies or without either evidence of  
15 additional therapeutic benefit for the resident or clinical evidence that would warrant the continued  
16 use of the medication.

17 (3) "Duplicative Therapy" means multiple medications of the same pharmacological class or category  
18 or any medication therapy that replicates a particular effect of another medication that the individual  
19 is taking.

20 (4) "Indications for the prescription" means a documented clinical rationale for administering a  
21 medication that is based upon an assessment of the resident's condition and therapeutic goals and is  
22 consistent with manufacturer's recommendations.

23 (5) "Monitoring" means ongoing collection and analysis of information (such as observations and  
24 diagnostic test results) and comparison to baseline data in order to:

25 (A) Ascertain the individual's response to treatment and care, including progress or lack of  
26 progress toward a therapeutic goal;

27 (B) Detect any complications or adverse consequences of the condition or of the treatments;  
28 and

29 (C) Support decisions about modifying, discontinuing, or continuing any interventions.

30 (c) Antipsychotic therapy shall not be initiated on any patient unless necessary to treat a clinically diagnosed and  
31 clinically documented condition. When antipsychotic therapy is prescribed, unless clinically contraindicated, gradual  
32 dose reductions and behavioral interventions shall be employed in an effort to discontinue these drugs. "Gradual dose  
33 reduction" means the stepwise tapering of a dose to determine if symptoms, conditions or risks can be managed by a  
34 lower dose or if the dose or the medication can be discontinued.

35 (d) The facility shall ensure that procedures aimed at minimizing medication error rates include the following:

36 (1) All medications or drugs and treatments shall be administered and discontinued in accordance with  
37 signed medical orders with are recorded in the patient's medical record. Such orders shall be

1 complete and include drug name, strength, quantity to be administered, route of administration,  
2 frequency and, if ordered on an as-needed basis, a stated indication for use.

- 3 (2) The requirements for self-administration of medication shall include the following:
- 4 (A) determination by the interdisciplinary team that this practice is safe;
  - 5 (B) administration ordered by the physician or other person legally authorized to prescribe  
6 medications;
  - 7 (C) instructions for administration printed on the medication label; and
  - 8 (D) administration of medication monitored by the nursing staff and consultant pharmacist.
- 9 (3) The administration of one patient's medications to another patient is prohibited except in the case  
10 of an emergency. In the event of such emergency, the facility shall ensure that the borrowed  
11 medications are replaced and so documented.
- 12 (4) Omission of medications and the reason for omission shall be indicated in the patient's medical  
13 record.
- 14 (5) Medication administration records shall provide time of administration, identification of the drug  
15 and strength of drug, quantity of drug administered, route of administration, frequency,  
16 documentation sufficient to determine the staff who administered the drugs. Medication  
17 administration records shall indicate documentation of injection sites and topical medication sites  
18 requiring rotation of transdermal medication.
- 19 (6) The pharmacy shall receive an exact copy of each physician's order for medications and treatments.
- 20 (7) When medication orders do not state the number of doses or days to administer the medication, the  
21 facility shall implement automatic stop orders according to manufacturer's recommendations.
- 22 (8) The facility shall maintain an accountability of controlled substances as defined by the North  
23 Carolina Controlled Substances Act, G.S. 90, Article 5.

24  
25 *History Note: Authority G.S. 131E-104;*  
26 *Eff. January 1, 1996;*  
27 *Amended Eff. January 1, 2013;*  
28 *Pursuant to G.S. 150B-21.3A, a rule is necessary without substantive public interest Eff. March 22,*  
29 *~~2015-2015;~~*  
30 *Pursuant to G.S. 150B-21.3A, rule is necessary Eff. April 2, 2025;*  
31 *Readopted Eff. ~~August 1, 2026-May 1, 2026.~~*